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To find out whether ultrasound-guided fine-needle aspiration (FNA) and ultrasound and stereotactic-guided large core needle biopsy
(LCNB) are reliable alternatives to needle-localised open breast biopsy (NLBB) in daily practice, we performed a retrospective study
and evaluated the validity of these methods. In all, 718 women with 749 nonpalpable breast lesions from three Dutch Hospitals were
included, and the validity of the various methods for diagnosis was assessed. This was carried out according to a method described by
Burbank and Parker for evaluating the quality of an image-guided breast intervention. We compared our results with the outcome of
the COBRA study. Overall, all diagnostic strategies (NLBB, FNA, LCNB ultrasound and stereotactic guided) show comparable
agreement rates. However, the miss rates differ: 2% for NLBB, 3% for COBRA (LCNB in study setting), 5% for FNA and 8–12% for
LCNB in practice. Fine-needle aspiration was nonconclusive in 29%, and shows an overestimation for DCIS in 9%. The DCIS
underestimate rate in NLBB was 8%. For the assessment of lesions consisting of microcalcifications only and to exclude malignancy in
all other lesions, a 14-gauge needle should be used. Ultrasound-guided intervention can be performed in a large percentage of
nonpalpable lesions. Lesions consisting only of microcalcifications on mammography need special attention.
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Needle-localised open breast biopsy (NLBB) is considered the gold
standard procedure for the diagnosis of nonpalpable breast lesions
(NPBL) (Jackman and Marzoni, 1997). Needle-localised open
breast biopsy is a surgical procedure with high costs and for most
of the patients, is a traumatic experience. In the past few decades,
less traumatic and cost-saving nonoperative image-guided techni-
ques, such as fine-needle aspiration (FNA) and large-core needle
biopsy (LCNB), have been advocated as an alternative to surgery to
obtain material for a microscopic diagnosis. For guidance,
ultrasound or stereotaxis are advocated.
Recently, a large prospective study on stereotactic-guided LCNB
was performed in the Netherlands to evaluate the diagnostic
accuracy of this method (COBRA study) (Verkooijen, 2002). This
study included 973 patients with 1029 nonpalpable breast lesions
and showed a sensitivity rate of 97% and a specificity rate of 99%
for stereotactic-guided LCNB. These figures are comparable to
NLBB (Jackman and Marzoni, 1997). In the Dutch study, the
stereotactic LCNB was always performed on a dedicated prone
table, in an optimal setting. The dedicated equipment appears to
be highly reliable but has the disadvantage of high initial expense.
Therefore, it is not widely available in the Netherlands. The other
alternatives for NLBB, such as stereotactic-guided LCNB with
upright mammography machine and add on digital attachment,
ultrasound-guided FNA and LCNB are more widely available. To
find out whether FNA (ultrasound-guided) and LCNB (ultrasound
and stereotactic-guided) are reliable alternatives to NLBB in daily
practice, a retrospective study on the diagnostic accuracy of these
different techniques was performed in three hospitals in the
Netherlands.
The aim of this study was to evaluate the method of choice for
intervention and type of guidance with respect to the mammo-
graphic characteristics of the lesion.
We present the results of 718 women with 749 nonpalpable
breast lesions diagnosed with NLBB, FNA and LCNB in three
hospitals in the Netherlands, and compare these results with the
outcome of the COBRA study (Verkooijen, 2002).
PATIENTS AND METHODS
In this study, all patients were included with a mammographic
suspect, nonpalpable lesion in a defined calendar period, who were
referred for diagnostic work-up at three different hospitals in the
Netherlands: the University Medical Centre Utrecht (UMCU), the
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lUniversity Medical Centre Nijmegen (UMCN) and the Antoni
van Leeuwenhoek Hospital Amsterdam (AvL). These three
hospitals were chosen because of their different strategies and
their large experience in diagnostic work-up for patients referred
with nonpalpable breast lesions. Patients were identified by
means of the hospital registry. We used the central computer
systems of the hospital registrations to obtain the records of
all patients who underwent an NLBB or an image-guided
breast intervention. A total of 202 women were identified at the
UMCU (January 1996–December 1999), 237 women at the UMCN
(January 1996–December 1999) and 279 women at the AvL
(January 1997–December 1999). These 718 women had 749
nonpalpable mammographic suspect lesions. The records of all
radiological and pathological breast examinations were collected.
The following data were abstracted: patient characteristics, type of
imaging technique used at first examination, mammographic
lesion characteristics, ultrasound lesion characteristics, biopsy
method (NLBB, FNA, LCNB), pathological lesion characteristics
and imaging follow-up results.
Needle-localised open breast biopsy was performed as a primary
diagnostic procedure as well as a secondary diagnostic procedure
for confirmation after FNA or core biopsy. In cases of NLBB, the
needle was placed with ultrasound guidance or X-ray guidance
using a coordinate grid or stereotaxis.
Fine needle assay was performed with a 22-gauge needle and a
10-ml syringe. Adequate needle position was controlled by real-
time visualisation of the tip-echo in the lesion.
Stereotactic-guided LCNB was performed at the UMCN with a
conventional add-on device and at the UMCU with a digital
dedicated prone table. At the UMCN, for all LCNB an 18-gauge
needle was used. The other hospitals used a 14-gauge long throw
needle. The number of passes varied from two to three with
ultrasound guidance. With stereotactic guidance, the number of
passes varied from two to three at the UMCN, but at the UMCU a
minimum of five passes were taken.
We assessed the validity of NLBB, FNA and LCNB (ultrasound
and stereotactic). This was carried out according to the method of
Burbank and Parker (1998), which uses a four by four table,
instead of a two by two table for the analysis. (Table 1) In the
latter, much important clinical information is lost, while the
former allows not only the distinction between benign and
malignant lesions but also to include in the analysis pathologic
findings such as atypical ductal hyperplasia (ADH), ductal
carcinoma in situ (DCIS) or infiltrating breast cancer. Atypical
ductal hyperplasia lesions are often small and therefore the
identification of ADH in a surgical specimen is nearly always an
incidental finding without therapeutic consequences (Tavassoli,
1998). Nevertheless, ADH found in a core biopsy specimen has
clinical consequences because in a high percentage it is associated
with malignancy (Liberman et al, 1995). The difference between
DCIS and invasive breast cancer has clinical consequences. If a
lesion was diagnosed with LCNB as ADH, DCIS or invasive breast
cancer, but the surgical excision showed a lower degree of
pathology, it is more appropriate to regard this as an agreement
rather than an overestimate. It happens that an accurately
diagnosed lesion at needle sampling is not again identified at
surgical biopsy, because the lesion was already totally removed at
needle sampling, or the lesion was not adequately removed at
surgery.
We had to make an adjustment of the four by four table for FNA.
With FNA, it is not possible to determine whether a malignancy is
invasive or not. In our model, when the FNA was reported
malignant, it is regarded as an agreement only if the histological
diagnosis after surgery was invasive breast cancer. If the
histological diagnosis after surgery was DCIS, we regarded it a
‘DCIS overestimate’. In the table, we added a column ‘nonconclu-
sive’ to be able to evaluate the number of insufficient samples.
Since we used retrospective data from on-going clinical practice,
the NLBB (gold standard) was not available for all patients. For
these patients, we used follow-up data to assume the absence of
malignancy. In case the follow-up was too short, we assumed
correctness of the primary diagnostic procedure to estimate the
upper border of the rates (sensitivity analysis).
Data were administered and analysed using the Statistical
Package for Social Sciences 8.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
In Table 2, the characteristics of the patients and the results of the
radiological examinations are presented. The mean age of the
patients was 54.7 years (range 21–85 years) In all, 208 (27.8%)
lesions were screen detected. Of all 749 lesions, 729 (97.3%) were
examined with mammography; 223 (30.6 %) showed only
microcalcifications, 433 (59.4 %) showed a mass (including
densities, densities with microcalcifications and spiculated masses)
and 56 (7.7%) were not visible at mammography. The mean
diameter of the lesions (according to the radiological examina-
tions) was 13.9mm. Malignancy was diagnosed in 378 (50.4%)
lesions, DCIS in 102 out of 378 (27.0%) and invasive carcinoma in
276 out of378 (73.0%).
A primary surgical diagnostic approach was performed in 316
out of 749 (42.2%) cases. In 176 cases, the lesion consisted of
microcalcifications only (55.6%). In four primary surgical
procedures, the amount of tissue removed was not sufficient for
reliable diagnosis (1.3%). The procedure failed six times because
the lesion was not removed (2%). Of these six lesions, two were
removed during a second operation and four were followed
Table 1 Adjusted Burbank & Parker method for the evaluation of results of image-guided intervention and histological findings at surgical excision
Histologic findings of surgical excision
Image-guided intervention Nonconclusive Benign High risk DCIS Invasive carcinoma
Nonconclusive NC NC NC NC
Benign A U (agreement) U (miss) U (miss)
High risk (histology) O (agreement) A U (HR underestimate) U (HR underestimate)
DCIS O O A U (DCIS underestimate)
Invasive carcinoma O (agreement) O (agreement) O (agreement) A
Malignancy on cytology O (overestimate) O (overestimate) O (DCIS overestimate) A
Agreement¼the patient management was correct on behalf of the pathology findings on core biopsy; miss¼core biopsy missed the clinically relevant malignancy (in situ or
invasive); HR underestimate¼although a high-risk lesion was found on core biopsy and the appropriate clinical management was taken (surgical biopsy), the malignancy (in situ or
invasive) was missed on core; DCIS underestimate¼in the surgical specimen for the treatment of DCIS found on core biopsy, an invasive component was discovered;
Overestimate¼although malignant cells were found on FNA, no invasive carcinoma was found in the surgical specimen. NC¼nonconclusives; A¼agreements;
O¼overestimates; U¼underestimates.
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lradiologically. The results of the 312 lesions were: 129 benign, 23
high-risk (ADH, lobular carcinoma in situ), 74 DCIS and 86
invasive carcinoma. Six patients who were initially diagnosed as
having DCIS also showed invasive carcinoma on therapeutic
excision (DCIS underestimate rate 8%).
Fine-needle aspiration was followed by NLBB in 148 out of 242
lesions (61.2%). The results are presented in Table 3. Fine-needle
aspiration was nonconclusive in 70 out of 242 cases (29%). There
were 98 agreements, 10 overestimates and five misses. For 94
lesions (38.8%), NLBB was not available. Of these 94, 17 cases were
followed radiologically after a nonconclusive FNA (3–33 months;
mean 13.8) and one carcinoma was found on follow-up. A total of
22 lesions with a benign result on FNA were followed radiologically
(4–38 months; mean 13.4), so far without any suspect abnorm-
Table 2 Characteristics of the study population
Total population UMCU UMCN AvL
Number of patients 718 202 237 279
Number of lesions 749 211 255 283
Age (range) 54.7 (21–85) 52.8 (24–85) 54.8 (26–84) 55.9 (21–83)
Reason for examination
Screen-detected lesions 208 (27.8) 56 (26.5) 90 (35.3) 62 (21.9)
Family history of breast cancer 98 (13.6) 27 (13.4) 49 (20.7) 22 (7.9)
History of breast cancer 136 (18.9) 33 (16.3) 39 (16.5) 64 (22.9)
Other
a 155 (21.6) 58 (28.7) 54 (22.8) 43 (15.4)
Unknown 152 (21.2) 37 (18.3) 23 (9.7) 92 (32.9)
Mammography 729 (97.3) 208 (98.6) 245 (96.1) 276 (97.5)
Only microcalcifications 223 (30.6) 63 (30.3) 73 (29.7) 87 (31.5)
Density with microcalcifications 85 (11.7) 18 (8.7) 33 (13.5) 34 (12.3)
Density 252 (34.5) 72 (34.6) 81 (33.1) 99 (35.9)
Spiculated density 96 (13.2) 22 (10.5) 32 (13.1) 42 (15.3)
Focal asymmetry 3 (0.4) 1 (0.5) 2 (0.8) 0
Architectural distortion 12 (1.6) 1 (0.5) 9 (3.7) 2 (0.7)
Not visible 56 (7.7) 31 (14.9) 15 (6.1) 10 (3.6)
Unknown 2 (0.3) 0 0 2 (0.7)
Ultrasonography
Number (% of lesion per clinic) 567 (75.7) 135 (64.0) 202 (79.2) 230 (81.3)
Solid 410 (72.3) 110 (81.5) 128 (63.4) 172 (74.8)
Both solid and cystic 16 (2.8) 6 (4.4) 7 (3.5) 3 (1.3)
Not described 16 (2.8) 1 (0.7) 8 (3.9) 7 (3.0)
Not visible 125 (22.1) 18 (13.4) 59 (29.2) 48 (20.9)
Radiologic diameter of lesion
No. of cases known (%) 450 (60.1) 84 (39.8) 169 (66.3) 197 (69.6)
mm (s.d.) 13.9 (10.8) 10.9 (5.3) 16.3 (12.7) 13.0 (10.3)
Primary diagnostic intervention
Diagnostic surgery 316 (42.2) 79 (37.4) 129 (50.6) 108 (38.2)
FNA ultrasound guided 242 (32.3) 72 (34.1) 0 170 (60.1)
LCNB ultrasound guided 128 (17.1) 21 (10.0) 102 (40.0) 5 (1.7)
LCNB stereotactic guided 63 (8.4) 39 (18.5) 24 (9.4) 0
Malignant lesions (histology)
b 378 (50.4) 84 (39.8) 130 (50.9) 164 (57.9)
DCIS 102 (27.0) 26 (31.0) 34 (26.2) 42 (25.6)
Invasive carcinoma 276 (73.0) 58 (69.0) 96 (73.8) 122 (74.4)
aIncludes: palpable lesion somewhere else in the breast(s), follow-up for benign condition in the past, pain, hormone replacement therapy.
bHistology report from surgical
specimen (‘Gold standard’)
Table 3 Comparison of cytologic findings of FNA to histological findings of surgical excision
Histologic findings of surgical excision
No surgical confirmation
a Nonconclusive Benign High risk DCIS Invasive carcinoma Total
Cytologic findings
Nonconclusive 35 18 (NC) 2 (NC) 2 (NC) 13 (NC) 70
Benign 54 17 (A) 1 (M) 4 (M) 76
1 1
Malignancy 4 2 (O) 8 (O DCIS) 81 (A) 95
Total 94 0 37 2 11 98 242
aNo surgical confirmation at the hospital where the FNA was performed. NC¼nonconclusives; A¼agreements; M¼misses; O¼overestimates.
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lalities. Of these 22 cases, 21 were classified as BIRADS category 3;
one was classified as BIRADS 4. For 31 lesions, the period between
FNA and planned mammographical and clinical follow-up was too
short. The remaining 24 lesions were not planned for NLBB for
various reasons. (Cyst: seven; refused therapy: one; malignant
tumour (no breast cancer) found elsewhere: two; treatment in
another hospital: three; lost for follow-up: nine; LCNB with benign
result without follow-up: two).
For 89 out of 128 (69.5%) lesions that were examined with
LCNB under ultrasound guidance, a surgical excision was
performed. The results are shown in Table 4. There were 73
agreements, four underestimates and eight misses. The other four
were nonconclusive on LCNB. The gold standard procedure was
not available in 39 lesions (30.5%). Of these 39, a radiological
follow-up was available in 14 cases with benign result (2–34
months; mean 17.5). No carcinoma was found at follow-up. For
14 lesions, the period between LCNB and planned mammographi-
cal and clinical follow-up was too short to have follow-up data
yet. The reasons for the remaining 11 were: cyst: one; metastasis:
one; lost to follow-up: three; LCNB with benign result without
follow-up: six.
For lesions diagnosed by stereotactic LCNB, NLBB was available
in 54 out of 63 cases (85.7%). (Table 5) There were 44 agreements,
five underestimates and three misses. All the misses with
stereotactic-guided LCNB were found in the group of lesions
consisting of microcalcifications only. The other two were
nonconclusive on LCNB. For nine lesions (14.2%), a gold standard
procedure was not available. The reasons were treatment in
another hospital: one, lost for follow-up: two. In four cases with a
benign result, radiological follow-up was available (2–31 months;
mean 20.5). No carcinoma was found at follow-up. For two lesions,
the period between LCNB and planned follow-up was too short.
In Table 6, the agreement, underestimate and miss rates are
presented and compared with the results from the COBRA study.
Sensitivity analysis was used to quantify the impact of patient
selection for additional NLBB. The miss rate and sensitivity rate
remains the same, since we assume them to be nonmalignant.
Agreement rates increase: for FNA from 87 to 91%, for ultrasound-
guided LCNB from 86 to 90% and for stereotactic-guided LCNB
from 85 to 87%.
DISCUSSION
Overall, all diagnostic strategies (NLBB, FNA, LCNB ultrasound
and stereotactic guided) show comparable agreement rates.
However, the miss rates differ: 2% for NLBB, 3% for COBRA
(LCNB in study setting), 5% for FNA and 8–12% for LCNB in
practice, respectively.
Ductal carcinoma in situ underestimate (the finding of DCIS
without invasive carcinoma in the diagnostic material, but with
invasive carcinoma in the therapeutically specimen) varies from
8% (NLBB) to 37% (LCNB ultrasound guided). The difference in
treatment of in situ and invasive carcinoma with respect to the
Table 4 Comparison of histologic findings of LCNB US-guided to histological findings of surgical excision
Histologic findings of surgical excision
No surgical confirmation
a Nonconclusive Benign High risk DCIS Invasive carcinoma Total
LCNB US-guided
Nonconclusive 1 1 (NC) 3 (NC) 5
Benign 34
17 (A)
2 (A) 2 (M) 6 (M) 61
High risk 1 1 (A) 1 (U HR) 3
DCIS 5 (A) 3 (U DCIS) 8
Invasive carcinoma 3 48 (A) 51
Total 39 0 18 3 7 61 128
aNo surgical confirmation in the hospital where the US-guided LCNB was performed. US-guided¼ultrasound guided. NC¼nonconclusives; A¼agreements; M¼misses;
U¼underestimates.
Table 5 Comparison of histologic findings of LCNB stereotactic guided to histological findings of surgical excision
Histologic findings of surgical excision
No surgical confirmation
a Nonconclusive Benign High risk DCIS Invasive carcinoma Total
LCNB stereotactic
Nonconclusive 1 (NC) 1 (NC) 2
Benign 8 10 (A) 1 (A) 3 (M) 22
High risk 2 (A) 1 (A) 2 (U HR) 5
DCIS 8 (A) 3 (U DCIS) 11
Invasive carcinoma 1 22 (A) 23
Total 9 0 13 2 14 25 63
aNo surgical confirmation in the hospital where the stereotactic-guided LCNB was performed. NC¼nonconclusives; A¼agreements; M¼misses; U¼underestimates.
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laxilla makes this a serious clinical problem. Previous studies on
the underestimation of DCIS in a diagnostic surgery show figures
of 16 and 17% in a smaller series of patients (3 out of 19 and four
out of 24) (Thompson et al, 1991; Tartter et al, 1997). Our figure of
six out of 74 (8%) confirms the fact that DCIS underestimation is
also a problem in diagnostic NLBB. Ductal carcinoma in situ
underestimation of LCNB has often been considered as a specific
disadvantage of this technique, but every form of sampling,
whether surgical or image-guided minimal invasive, deals with this
problem. Therefore, the often results with respect to DCIS
underestimation in nonsurgical biopsy studies have to be
compared to the figures of surgical biopsies.
High-risk underestimate (the finding of ADH, lobular carcinoma
in situ without malignancy in the diagnostic material, but with
carcinoma (in situ or invasive), in the surgical specimen) varies
from 9% (NLBB) to 40% (LCNB stereotactic guided). In the
literature, figures of high-risk underestimate for 14-gauge needle
biopsy range from 14 to 58%. (Jackman et al, 1999; Verkooijen
et al, 2000) It is difficult to characterise the nonsurgical high-risk
group as a whole. Most frequently, this group is being used for
lesions with a microscopic pattern for which there is no consensus
in classification or in cases where final classification is difficult or
even impossible because of the small amount of tissue. Therefore,
high risk is frequently being used as an ‘escape category’ for
lesions difficult to diagnose (e.g. atypia at FNA and ADH at core
biopsy). In case of a lesion classified as high risk, a larger amount
of tissue is needed for final diagnosis.
In understanding the computed estimates, one should keep in
mind two aspects of patient selection. First, the selection of
primary diagnostic procedure in relation to the imaging char-
acteristics, and second patient selection for the surgical histo-
pathologic confirmation of the primary diagnostic procedure.
Fine-needle aspiration was only used with ultrasound guidance,
and therefore in selected cases. This selection was based on the
imaging characteristics of the lesion. Only 5.3% of the lesions
diagnosed with FNA consisted only of microcalcifications. For
the whole population, this figure was 30.6%. So, FNA was
mainly used in cases of lesions not just consisting of micro-
calcifications. For the interpretation of the miss rate figures this
is important to realise. It has been reported that miss rates
are higher in lesions consisting of microcalcifications (Lifrange
et al, 1997). Fine-needle aspiration shows a high percentage of
nonconclusive results (29%). This is a well-known major
disadvantage of the technique. The reported rates for insufficient
specimen with ultrasound-guided FNA vary from 0 to 38%
for nonpalpable lesions (Klijanienko et al, 1998). The success of
FNA is operator dependent (Masood, 1998). The best results have
been reported with an experienced operator performing the
aspirations. A multicentre clinical trial to evaluate FNA for
nonpalpable lesions performed by multiple operators was termi-
nated early because of the high rate of insufficient samples (Pisano
et al, 1998). Comparison of the two institutions where FNA was
performed in our study shows a percentage of nonconclusive
samples of 21.8% at the AvL and of 45.8% at the UMCU. At the
AvL, FNA is performed by a small group of radiologists and
dedicated cytopathologists. The results at the AvL compare well
with previous results (Ciatto et al, 1997). At the UMCU, the
aspiration is performed by a large group of radiologists and
residents. These high rates of insufficient samples as reported from
the UMCU make its use impractical in a clinical setting, and
supports the operator dependence as mentioned above. Another
well-known problem of FNA is the fact that it is not capable of
differentiating between in situ and invasive carcinoma in this
study, resulting in a DCIS overestimation rate (the finding of
malignant cells on cytology, and DCIS without invasive carcinoma
in the surgical specimen) of 9%. As mentioned above, the
difference in treatment of in situ and invasive carcinoma with
respect to the axilla makes this a serious clinical problem.
For ultrasound-guided LCNB, the lesion selection based on the
mammographic image was even more obvious. Only two cases
(1.6%) consisted of only microcalcifications on mammography.
Despite this selection, ultrasound-guided LCNB shows a relatively
high miss rate of 12%. The result of ultrasound-guided LCNB in
our study differs from the results in the literature on this subject.
One study showed almost an equal accuracy with ultrasound-
guided LCNB compared to NLBB, using a 14-gauge needle and a
total of four to five passes (Parker et al, 1993). The 18-gauge needle
with two passes in our study was responsible for six of the eight
misses. This technique is definitely inferior to the one Parker
described and the one that was used in the COBRA study. There is
a discussion in the literature about whether an 18-gauge needle is
acceptable for ultrasound-guided LCNB (Cardenosa, 1999). With
respect to our figures, caution is warranted.
In stereotactic-guided LCNB, no selection was made. Half of the
lesions consisted of microcalcifications only (50.7%). All three
misses with stereotactic-guided LCNB were found in the group of
lesions consisting of only microcalcifications. If we compare the
two institutions where stereotactic-guided LCNB was performed,
there is a clear difference in outcome. This is probably due to the
technique used (18-gauge two to three passes (UMCN) vs 14-gauge
with a minimum of five passes (UMCU)). The 18-gauge needle
with two or three passes was responsible for 66.6% of the misses
and 50% of the underestimated high risks. Although the number of
cases with the 18-gauge needle is small, the figures are
disappointing. A previous study showed that a 14-gauge needle
provides the most accurate diagnosis, compared to 16- and 18-
gauge needles (Nath et al, 1995). Furthermore, the diagnostic
sensitivity is improved by increasing the number of cores taken to
Table 6 Agreement rate, underestimate and overestimate rates for the different primary diagnostic procedures
Surgical biopsy FNA US-guided LCNB US-guided LCNB stereotactic COBRA study
Needle (gauge) 22G 18G+14G 14G 14G
n¼ 316 148 89 54 858
Nonconclusive (%) 1.2 29 4 3 1.5
Agreement rate (%) Not applicable 87 86 85 93
Miss rate (%) 2 5 12 8 3
Sensitivity (%) 98 95 88 92 97
High risk underestimate rate (%)
a 9 Not applicable 33 40 23
DCIS underestimate rate (%)
b 8 Not applicable 37 27 17
DCIS overestimate rate (%)
c Not applicable 9 Not applicable Not applicable Not applicable
aHigh-risk underestimate is defined as the finding of ADH, lobular carcinoma in situ without malignancy in the diagnostic material, but with carcinoma (in situ or invasive), in the
surgical specimen
bDCIS underestimate is defined as the finding of DCIS without invasive carcinoma in the diagnostic material, but with invasive carcinoma in the therapeutical
specimen
cDCIS overestimate is defined as the finding of malignant cells on cytology and DCIS without invasive carcinoma in the surgical specimen. US-guided¼ultrasound
guided.
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lsix or more, particularly in women with mammographic micro-
calcifications of an equivocal nature (Rich et al, 1999). The
limitation in the assessment of the group ‘microcalcifications only’
indicates that a larger volume of tissue is necessary for a reliable
histopathalogic diagnosis. Therefore, in both North America and
many European breast diagnostic centres, vacuum-assisted core
biopsy is now extensively used. This technique has the ability to
obtain more diagnostic material during percutaneous biopsy
compared to 14-gauge core biopsy.
The second important aspect of patient selection in our study
(different from the COBRA, where all patients received a surgical
histopathologic confirmation) is the selection that was made by
surgeons of patients who underwent an ‘additional’ NLBB in cases
of a benign result. It is reasonable to assume that those patients for
whom the surgeon did not have a secure feeling about the benign
primary diagnosis were selected for NLBB. And therefore, those
patients not selected for subsequent NLBB have a correct primary
diagnosis. Taking this into account, we computed the maximum
agreement rates.
In conclusion, we found that FNA has a very high percentage of
nonconclusive results and has no place in the diagnosis of lesions
consisting of only microcalcifications. For the assessment of
lesions consisting of microcalcifications only and to exclude
malignancy in all other lesions, 18-gauge needle core biopsy is
unsuited. Ultrasound-guided intervention can be performed in a
large percentage of nonpalpable lesions. In a study setting, the
dedicated prone table used in combination with state-of-the-art
assessment protocols shows the best results. Lesions only
consisting of microcalcifications on mammography need special
attention.
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